Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Open-Label Study of FLUVIRIN 2006-2007 in Non-Elderly Adult and Elderly Subjects
2006-000787-88Phase 2Completed
- Sponsor
- Chiron Vaccines
- Start
- May 2006
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of influenza a virus a/singapore/gp1908/2015 ivr-180 (h1n1) antigen (uv, formaldehyde inactivated) in influenza (2 cohorts), sponsored by Chiron Vaccines. Primary endpoints: Haemagglutination inhibition antibody response at Day 21 and Safety of a single intramuscular injection of FLUVIRIN. Started May 2006; status: completed.
02
Drugs
influenza a virus a/singapore/gp1908/2015 ivr-180 (h1n1) antigen (uv, formaldehyde inactivated)
03
Conditions
influenza
Beyond the preview
Go deeper on 2006-000787-88.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000787-88.